Cervical Intraepithelial Neoplasia, Pipeline Review, H2 2019 – Bioleaders Corp, Elicio Therapeutics, Novan Inc & Vaccibody AS – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Cervical Intraepithelial Neoplasia (CIN) – Pipeline Review, H2 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering.

This Pharmaceutical and Healthcare latest pipeline guide Cervical Intraepithelial Neoplasia (CIN) – Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Cervical Intraepithelial Neoplasia (CIN) (Women’s Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Cervical Intraepithelial Neoplasia (CIN) (Women’s Health) pipeline guide also reviews of key players involved in therapeutic development for Cervical Intraepithelial Neoplasia (CIN) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 14, 6, 5 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 3, 2 and 4 molecules, respectively.

Cervical Intraepithelial Neoplasia (CIN) (Women’s Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.


  • The pipeline guide provides a snapshot of the global therapeutic landscape of Cervical Intraepithelial Neoplasia (CIN) (Women’s Health).
  • The pipeline guide reviews pipeline therapeutics for Cervical Intraepithelial Neoplasia (CIN) (Women’s Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Cervical Intraepithelial Neoplasia (CIN) (Women’s Health) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Cervical Intraepithelial Neoplasia (CIN) (Women’s Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Cervical Intraepithelial Neoplasia (CIN) (Women’s Health)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Cervical Intraepithelial Neoplasia (CIN) (Women’s Health).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Cervical Intraepithelial Neoplasia (CIN) (Women’s Health) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Key Topics Covered:

  • Introduction
  • Report Coverage
  • Cervical Intraepithelial Neoplasia (CIN) – Overview
  • Cervical Intraepithelial Neoplasia (CIN) – Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Cervical Intraepithelial Neoplasia (CIN) – Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Cervical Intraepithelial Neoplasia (CIN) – Companies Involved in Therapeutics Development
  • Altum Pharmaceuticals Inc
  • Antiva Biosciences Inc
  • Bioleaders Corp
  • Brooklyn ImmunoTherapeutics LLC
  • CEL-SCI Corp
  • Douglas Pharmaceuticals Ltd
  • Elicio Therapeutics
  • Genexine Inc
  • GenoLac BL Corp
  • Hefei Ruichengsheng Biotechnology Co Ltd
  • Inovio Pharmaceuticals Inc
  • KinoPharma Inc
  • Novan Inc
  • Papivax LLC
  • PDS Biotechnology Corp
  • Redbiotec AG
  • Shanghai Bovax Biotechnology Co Ltd
  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
  • Shanghai Institute of Biological Products Co Ltd
  • THEVAX Genetics Vaccine USA Inc
  • Transgene SA
  • Vaccibody AS
  • Vaxart Inc
  • ViciniVax BV
  • Cervical Intraepithelial Neoplasia (CIN) – Drug Profiles
  • (bizalimogene ralaplasmid + mavilimogene ralaplasmid) – Drug Profile
  • (lopinavir + ritonavir) – Drug Profile
  • ABI-1968 – Drug Profile
  • aminolevulinic acid hydrochloride – Drug Profile
  • AP-001 – Drug Profile
  • BLSILSB-710c – Drug Profile
  • BLSPGAC-10 – Drug Profile
  • Cellular Immunotherapy for Human Papillomavirus Infections – Drug Profile
  • Cellular Immunotherapy to Target HPV Protein E6 and E7 for Cervical Intraepithelial Neoplasia – Drug Profile
  • efineptakin alfa – Drug Profile
  • Enzymes to Inhibit HPV E6 and E7 for Cervical Intraepithelial Neoplasia – Drug Profile
  • Gene Therapy for Human Papilloma Virus Associated Cervical Intraepithelial Neoplasia – Drug Profile
  • GLBL-101c – Drug Profile
  • GX-188E – Drug Profile
  • human papillomavirus (9 valent) vaccine – Drug Profile
  • human papillomavirus [serotypes 16, 18, 52, 58] (tetravalent, virus like particle) vaccine – Drug Profile
  • IGMKK-16E7 – Drug Profile
  • IRX-2 – Drug Profile
  • Multikine – Drug Profile
  • NSC-721689 – Drug Profile
  • PDS-0101 – Drug Profile
  • PVX-01 – Drug Profile
  • PVX-2 – Drug Profile
  • RKP-00156 – Drug Profile
  • RONC-3 – Drug Profile
  • tipapkinogene sovacivec – Drug Profile
  • TVGV-1 – Drug Profile
  • Vaccine to Target E7 for HPV Associated Cervical Intraepithelial Neoplasia – Drug Profile
  • Vaccine to Target HPV E6 for Cervical Intraepithelial Neoplasia And HPV Associated Head And Neck Squamous Cell Carcinoma – Drug Profile
  • VB-1016 – Drug Profile
  • VED-001 – Drug Profile
  • Vvax-001 – Drug Profile
  • VXAHPV-16.1 – Drug Profile
  • WH-504 – Drug Profile
  • WH-602 – Drug Profile
  • ZFN-603 – Drug Profile
  • ZFN-758 – Drug Profile
  • Cervical Intraepithelial Neoplasia (CIN) – Dormant Projects
  • Cervical Intraepithelial Neoplasia (CIN) – Discontinued Products
  • Cervical Intraepithelial Neoplasia (CIN) – Product Development Milestones
  • Featured News & Press Releases

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/vd5duo



Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.